Longevity nutrition company L-Nutra Health has launched a food-based programme, aiming to support Type 2 diabetes remission and reduce reliance on GLP-1 receptors.
The food programme is based on the Fasting Mimicking Diet (FMD), a patented, plant-based, low-glycemic protocol. For type 2 diabetes, multiple FMD cycles support glucose control, insulin sensitivity and visceral fat loss.
The company shares that with the rising use of weight loss medication, this launch is designed to offer a non-pharmaceutical approach that targets the root causes of metabolic disease, such as insulin resistance, muscle loss and cellular ageing.
Dr William Hsu, endocrinologist and CMO at L-Nutra Health, said, “For too long, diabetes care has focused on glucose management rather than resolution. At L-Nutra Health, we’re shifting the goalpost to remission. With nutrition at the core of our clinical approach, we’re helping patients not only reduce medications, but reclaim metabolic function and long-term vitality.”
L-Nutra will be exhibiting at the MLS Summit at CCR next month.